Bunkerhill MAC vs cmAngio®

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 60/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
by Bunkerhill Health
VS
by CureMetrix

AI Verdict

Tool A, Bunkerhill MAC, is designed to detect and quantify Mitral Annular Calcification (MAC) on routine CT scans for cardiovascular risk identification. In contrast, Tool B, cmAngio®, focuses on detecting Breast Arterial Calcifications (BAC) on mammograms to provide insights into cardiovascular health. While both leverage AI in medical imaging for cardiovascular risk assessment, they target different anatomical calcifications and utilize distinct imaging modalities.

Choose Bunkerhill MAC if…

Choose Bunkerhill MAC if your primary goal is to identify and quantify mitral annular calcification (MAC) from routine CT scans to assess broader cardiovascular risk. This tool is ideal for integrating MAC findings into a comprehensive care coordination strategy, leveraging its connection with the Carebricks generative AI platform for clinical reasoning and automated follow-up.

View Bunkerhill MAC →

Choose cmAngio® if…

Choose cmAngio® if you are looking to leverage existing mammography exams to gain insights into a woman's cardiovascular health by detecting breast arterial calcifications (BAC). This solution is particularly well-suited for integrating BAC identification and reporting into breast screening workflows, offering early cardiovascular risk assessment without additional procedures or radiation.

View cmAngio® →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature Bunkerhill MAC cmAngio®
Pricing Contact for pricing Paid, out-of-pocket
Deployment Cloud-based, integrated with existing EHRs and clinical systems via Carebricks platform. Cloud-based, integrates with any DICOM-compliant viewer
FDA Status Yes AI-estimated 1 AI-estimated
HIPAA Unknown Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

cmAngio®

Tool B (cmAngiou00ae) explicitly highlights 'Quick and easy installation (less than an hour)' and 'Compatible with any DICOM-compliant viewer,' suggesting a straightforward setup and integration into existing radiology workflows. While Tool A (Bunkerhill MAC) mentions 'seamless integration with existing EHRs and clinical systems,' Tool B's specific claims about rapid installation and broad viewer compatibility provide a stronger indication of immediate usability for radiologists.

Clinical Value

Tie

Both tools are FDA-cleared and offer significant clinical value by identifying cardiovascular risk markers from routine imaging (MAC on CT for Tool A, BAC on mammograms for Tool B). Tool A quantifies MAC, potentially offering more granular data, while Tool B processes both FFDM and DBT, broadening its applicability in mammography. Both address critical, often overlooked, cardiovascular risk factors, making their clinical contributions equally valuable in their respective domains.

Pricing & Value

cmAngio®

Both tools require direct contact for pricing information. However, Tool B (cmAngiou00ae) explicitly mentions 'Limited-time offers for no-cost implementation and service may be available,' which indicates a potential for greater value or more flexible pricing models for prospective customers. This transparency about potential cost-saving opportunities gives it a slight edge.

Enterprise Readiness

cmAngio®

Tool B (cmAngiou00ae) explicitly states it is 'Cybersecure and HIPAA-compliant,' which are crucial assurances for enterprise adoption in healthcare. While Tool A (Bunkerhill MAC) states HIPAA compliance and BAA are 'likely, but not explicitly stated,' Tool B's direct affirmation provides greater confidence in its readiness for secure and compliant enterprise deployment.

Innovation

Bunkerhill MAC

Tool A (Bunkerhill MAC) emphasizes its integration with the 'Carebricks generative AI platform for clinical reasoning and action,' and its tagline is 'Generative AI for clinical reasoning and action.' This suggests a broader and more advanced application of AI beyond mere detection, aiming for automated workflows and deeper clinical insights. Tool B focuses on AI-based detection, which is innovative, but Tool A's generative AI approach appears to be a step further in AI application.

Support & Docs

Tie

Neither the provided structured facts nor readily available public web searches for 'Bunkerhill Health support documentation' or 'CureMetrix support documentation' offer specific details regarding their support services or documentation. Without this information, it is not possible to distinguish between the two tools on this dimension.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature Bunkerhill MAC cmAngio®
AI Algorithm Focus Detects and quantifies Mitral Annular Calcification (MAC) on CT scans. Detects, quantifies, and contextualizes Breast Arterial Calcifications (BAC) on mammograms.
Imaging Modality Routine, non-gated chest CT scans. Full-Field Digital Mammography (FFDM) and Digital Breast Tomosynthesis (DBT) exams.
Company Bunkerhill Health CureMetrix
Key Feature Highlight Integrates with the Carebricks generative AI platform for clinical reasoning and action, supporting automated workflows for follow-up and care coordination. Provides visualization of BAC location on a scorecard, enables BAC identification and reporting without additional radiation or procedures.

Videos

Demos, reviews, and walkthroughs featuring Bunkerhill MAC and cmAngio®.

Loading videos…
Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

Bunkerhill MAC is an FDA-cleared AI algorithm that detects and quantifies mitral annular calcification (MAC) on routine CT scans, aiding early cardiovascular risk identification. cmAngiou00ae is FDA-cleared AI software for detecting Breast Arterial Calcifications (BAC) on mammograms, providing insights into cardiovascular health and aiding early risk assessment.
Bunkerhill MAC analyzes routine, non-gated chest CT scans. cmAngiou00ae processes both Full-Field Digital Mammography (FFDM) and Digital Breast Tomosynthesis (DBT) exams.
Bunkerhill MAC is cloud-based and integrates with existing EHRs and clinical systems via the Carebricks generative AI platform, supporting automated workflows for follow-up and care coordination. cmAngiou00ae is compatible with any DICOM-compliant viewer and is cybersecure and HIPAA-compliant, with quick and easy installation.
Bunkerhill MAC provides AI-powered detection and quantification of Mitral Annular Calcification (MAC) and integrates with the Carebricks platform for clinical reasoning and action. cmAngiou00ae offers AI-based detection of Breast Arterial Calcifications (BAC) and provides visualization of BAC location on a scorecard.
Bunkerhill MAC aids early cardiovascular risk identification and care coordination by identifying patients at increased cardiovascular risk from routine CT scans. cmAngiou00ae enables BAC identification and reporting without additional radiation or procedures, providing insights into cardiovascular health and aiding early risk assessment for women.

Backers

Who funded each tool's parent company.

cmAngio®

AI Tool Finder
AI-powered search. Results may not be comprehensive.